Peptide Cancer Vaccine Market

Chapter 1 Peptide Cancer Vaccine Market Overview

1.1 Peptide Cancer Vaccine Definition

1.2 Global Peptide Cancer Vaccine Market Size Status and Outlook (2019-2032)

1.3 Global Peptide Cancer Vaccine Market Size Comparison by Region (2019-2032)

1.4 Global Peptide Cancer Vaccine Market Size Comparison by Type (2019-2032)

1.5 Global Peptide Cancer Vaccine Market Size Comparison by Application (2019-2032)

1.6 Global Peptide Cancer Vaccine Market Size Comparison by Sales Channel (2019-2032)

1.7 Peptide Cancer Vaccine Market Dynamics

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Products Launch, Mergers, Acquisitions, Expansion, Agreement and Collaborations, Partnerships)

1.7.4 COVID-19 Impacts

1.7.5 Russia-Ukraine War Impacts

1.7.6 US-Israel-Iran War Impacts

Chapter 2 Executive Summary

2.1 Global Peptide Cancer Vaccine Market Snapshot

2.2 Global Peptide Cancer Vaccine Market Volume & Revenue 2019-2025

2.3 Global Peptide Cancer Vaccine Market Differential Growth Potential Analysis by Type, 2019-2032 (USD Million)

2.4 Global Peptide Cancer Vaccine Market Differential Growth Potential Analysis by Application, 2019-2032 (USD Million)

2.5 Global Peptide Cancer Vaccine Market Differential Growth Potential Analysis by Sales Channels, 2019-2032 (USD Million)

2.6 Global Peptide Cancer Vaccine Market Differential Growth Potential Analysis by Region, 2019-2032 (USD Million)

Chapter 3 Peptide Cancer Vaccine Market Segment Analysis by Player

3.1 Global Peptide Cancer Vaccine Sales and Market Share by Player (2023-2025)

3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Player (2023-2025)

3.3 Global Peptide Cancer Vaccine Average Price by Player (2023-2025)

3.4 Players Competition Situation & Trends (2023-2025)

3.5 Conclusion of Segment by Player

Chapter 4 Peptide Cancer Vaccine Market Segment Analysis by Type

4.1 Global Peptide Cancer Vaccine Market by Type

4.1.1 ITK-1

4.1.2 GRN-1201

4.1.3 TPIV200

4.1.4 TPIV110

4.1.5 UV1

4.1.6 Galinpepimut-S

4.1.7 TARP 27-35

4.1.8 HER-Vaxx

4.1.9 Vx-001

4.1.10 Others

4.2 Global Peptide Cancer Vaccine Sales and Market Share by Type (2019-2025)

4.3 Global Peptide Cancer Vaccine Revenue and Market Share by Type (2019-2025)

4.4 Global Peptide Cancer Vaccine Average Price by Type (2019-2025)

4.5 Leading Players of Peptide Cancer Vaccine by Type in 2025

4.6 Conclusion of Segment by Type

Chapter 5 Peptide Cancer Vaccine Market Segment Analysis by Application

5.1 Global Peptide Cancer Vaccine Market by Application

5.1.1 Breast Cancer

5.1.2 Lung Cancer

5.1.3 Melanoma

5.1.4 Prostate Cancer

5.1.5 Others

5.2 Global Peptide Cancer Vaccine Revenue and Market Share by Application (2019-2025)

5.3 Leading Consumers of Peptide Cancer Vaccine by Application in 2025

5.4 Conclusion of Segment by Application

Chapter 6 Peptide Cancer Vaccine Market Segment Analysis by Sales Channel

6.1 Global Peptide Cancer Vaccine Market by Sales Channel

6.1.1 Global Peptide Cancer Vaccine Market, by Direct Channel Market Analysis 2019-2032 (USD Million)

6.1.2 Global Peptide Cancer Vaccine Market, by Distribution Channel Market Analysis 2019-2032 (USD Million)

6.2 Global Peptide Cancer Vaccine Revenue and Market Share by Sales Channel (2019-2025)

6.3 Leading Distributors/Dealers of Peptide Cancer Vaccine by Sales Channel in 2025

6.4 Conclusion of Segment by Sales Channel

Chapter 7 Peptide Cancer Vaccine Market Segment Analysis by Region

7.1 Global Peptide Cancer Vaccine Market Size and CAGR by Region (2019-2032)

7.2 Global Peptide Cancer Vaccine Sales and Market Share by Region (2019-2025)

7.3 Global Peptide Cancer Vaccine Revenue and Market Share by Region (2019-2025)

7.4 North America

7.4.1 North America Market by Country

7.4.2 North America Peptide Cancer Vaccine Market Share by Type

7.4.3 North America Peptide Cancer Vaccine Market Share by Application

7.4.4 United States

7.4.5 Canada

7.4.6 Mexico

7.5 Europe

7.5.1 Europe Market by Country

7.5.2 Europe Peptide Cancer Vaccine Market Share by Type

7.5.3 Europe Peptide Cancer Vaccine Market Share by Application

7.5.4 Germany

7.5.5 United Kingdom

7.5.6 France

7.5.7 Italy

7.5.8 Russia

7.5.9 Spain

7.5.10 Benelux

7.5.11 Poland

7.5.12 Austria

7.5.13 Portugal

7.5.14 Rest of Europe

7.6 Asia-Pacific

7.6.1 Asia-Pacific Market by Country

7.6.2 Asia-Pacific Peptide Cancer Vaccine Market Share by Type

7.6.3 Asia-Pacific Peptide Cancer Vaccine Market Share by Application

7.6.4 China

7.6.5 Japan

7.6.6 Korea

7.6.7 India

7.6.8 Southeast Asia

7.6.9 Australia

7.6.10 Taiwan

7.6.11 Rest of Asia Pacific

7.7 South America

7.7.1 South America Market by Country

7.7.2 South America Peptide Cancer Vaccine Market Share by Type

7.7.3 South America Peptide Cancer Vaccine Market Share by Application

7.7.4 Brazil

7.7.5 Argentina

7.7.6 Colombia

7.7.7 Chile

7.7.8 Peru

7.7.9 Venezuela

7.7.10 Rest of South America

7.8 Middle East & Africa

7.8.1 Middle East & Africa Market by Country

7.8.2 Middle East & Africa Peptide Cancer Vaccine Market Share by Type

7.8.3 Middle East & Africa Peptide Cancer Vaccine Market Share by Application

7.8.4 UAE

7.8.5 Saudi Arabia

7.8.6 South Africa

7.8.7 Egypt

7.8.8 Nigeria

7.8.9 Rest of Middle East & Africa

7.9 Conclusion of Segment by Region

Chapter 8 Profile of Leading Peptide Cancer Vaccine Players

8.1 Boston Biomedical

8.1.1 Company Snapshot

8.1.2 Product/Service Offered

8.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.1.4 Recent Developments

8.2 Ultimovacs

8.2.1 Company Snapshot

8.2.2 Product/Service Offered

8.2.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.2.4 Recent Developments

8.3 BrightPath Biotherapeutics

8.3.1 Company Snapshot

8.3.2 Product/Service Offered

8.3.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.3.4 Recent Developments

8.4 TapImmune

8.4.1 Company Snapshot

8.4.2 Product/Service Offered

8.4.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.4.4 Recent Developments

8.5 Immatics

8.5.1 Company Snapshot

8.5.2 Product/Service Offered

8.5.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.5.4 Recent Developments

8.6 Sellas

8.6.1 Company Snapshot

8.6.2 Product/Service Offered

8.6.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.6.4 Recent Developments

8.7 Imugene

8.7.1 Company Snapshot

8.7.2 Product/Service Offered

8.7.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.7.4 Recent Developments

8.8 VAXON Biotech

8.8.1 Company Snapshot

8.8.2 Product/Service Offered

8.8.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.8.4 Recent Developments

8.9 Generex Biotechnology

8.9.1 Company Snapshot

8.9.2 Product/Service Offered

8.9.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.9.4 Recent Developments

8.10 ISA Pharmaceuticals

8.10.1 Company Snapshot

8.10.2 Product/Service Offered

8.10.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.10.4 Recent Developments

8.11 OncoTherapy Science

8.11.1 Company Snapshot

8.11.2 Product/Service Offered

8.11.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)

8.11.4 Recent Developments

Chapter 9 Upstream and Downstream Analysis of Peptide Cancer Vaccine

9.1 Industrial Chain of Peptide Cancer Vaccine

9.2 Upstream of Peptide Cancer Vaccine

9.2.1 Raw Materials (If Applicable)

9.2.2 Manufacturing Cost Structure (If Applicable)

9.2.3 Manufacturing Process (If Applicable)

9.3 Downstream of Peptide Cancer Vaccine

9.3.1 Leading Distributors/Dealers of Peptide Cancer Vaccine

9.3.2 Leading Consumers of Peptide Cancer Vaccine

Chapter 10. Global Peptide Cancer Vaccine Market Industry Analysis

10.1. Porter's Five Forces Analysis

10.1.1. Threat of New Entrants

10.1.2. Bargaining Power of Buyers/Consumers

10.1.3. Bargaining Power of Suppliers

10.1.4. Threat of Substitute Types

10.1.5. Intensity of Competitive Rivalry

10.2. Major Growth Avenues within Global Peptide Cancer Vaccine Market

10.2.1. Product Types

10.2.2. Applications

10.2.3. Sales Channels

10.2.4. Country

10.3. Peptide Cancer Vaccine Industry Ecosystem

10.4. Price Trend Analysis (If Applicable)

10.5. Buying Criteria (If Applicable)

10.6. Regulations (If Applicable)

Chapter 11 Development Trend of Peptide Cancer Vaccine (2026-2032)

11.1 Global Peptide Cancer Vaccine Market Size (Sales and Revenue) Forecast (2026-2032)

11.2 Global Peptide Cancer Vaccine Market Size and CAGR Forecast by Region (2026-2032)

11.3 Global Peptide Cancer Vaccine Market Size and CAGR Forecast by Type (2026-2032)

11.4 Global Peptide Cancer Vaccine Market Size and CAGR Forecast by Application (2026-2032)

11.5 Global Peptide Cancer Vaccine Market Size and CAGR Forecast by Sales Channel (2026-2032)

Chapter 12. Import - Export Analysis (If Applicable)

12.1 North America Peptide Cancer Vaccine Import-Export, 2019-2025

12.2 Europe Peptide Cancer Vaccine Import-Export, 2019-2025

12.3 Asia Pacific Peptide Cancer Vaccine Import-Export, 2019-2025

12.4 South America Peptide Cancer Vaccine Import-Export, 2019-2025

12.5 Middle East & Africa Peptide Cancer Vaccine Import-Export, 2019-2025

Chapter 13. Demand-Supply Gap Analysis (If Applicable)

13.1 North America Peptide Cancer Vaccine Demand-Supply, 2019-2025

13.2 Europe Peptide Cancer Vaccine Demand-Supply, 2019-2025

13.3 Asia Pacific Peptide Cancer Vaccine Demand-Supply, 2019-2025

13.4 South America Peptide Cancer Vaccine Demand-Supply, 2019-2025

13.5 Middle East & Africa Peptide Cancer Vaccine Demand-Supply, 2019-2025

Chapter 14 Appendix

14.1 Research Methodology

14.2 Data Sources